The pathway begins with a medical consultation rather than a purchase decision. A physician — typically an endocrinologist for adult cases or a pediatric endocrinologist for children — evaluates presenting symptoms and determines whether further diagnostic workup is warranted.
This consultation step exists precisely because HGH is a prescription-only pharmaceutical; there is no legitimate route to treatment that bypasses medical evaluation.
If clinically indicated, the physician orders diagnostic testing following established clinical guidelines, typically starting with IGF-1 blood levels and proceeding to formal GH stimulation testing where indicated. In children, growth-curve data supplements the lab findings.
This testing step confirms an approved indication before any prescription decision is made, ensuring treatment is directed at a diagnosed condition rather than a general request.
Once testing confirms an approved indication, the prescribing physician — who must be registered with the UAE Ministry of Health and Prevention — issues a formal prescription. This step is legally distinct from the diagnostic consultation and carries its own regulatory requirements.
The prescription specifies a course of treatment determined entirely by the physician based on the confirmed diagnosis, not by patient preference or online research.
The prescription must then be filled through a pharmacy licensed and regulated by MoHAP — no other dispensing channel is legally recognized. Ongoing treatment typically involves regular follow-up appointments and repeat lab monitoring managed by the prescribing physician.
This article describes the general regulatory pathway reported for prescription medicines in the UAE, not a step-by-step personal guide or medical advice. REVIVE LAB UAE is a research-peptide supplier, not a pharmacy or clinic, and does not participate in this process or sell HGH.